Expert Interview
Discussing Familial Chylomicronemia Syndrome (FCS), volanesorsen, and the recent Phase 3 topline results of olezarsen.
Ticker(s): IONSInstitution: Western University
- Distinguished Professor of Medicine and Biochemistry at Western University in London, Ontario, Canada.
- Manages >2500 patients in his lipid clinic, 25 with FCS.
- His laboratory discovered the causal genes and first pathogenic variants for >20 human diseases, and also developed the world’s first targeted next-generation sequencing panel for dyslipidemias.
- He was among the first in the world to use five medications that are now routinely prescribed to treat dyslipidemia or diabetes, has co-authored many clinical practice guidelines for cholesterol, blood pressure and diabete, and has published >900 papers.
How many patients with Familial Chylomicronemia Syndrome do you manage annually?
Added By: c_adminOn a scale from 1-10 how would you rate your level of excitement for volanesorsen and olezarsen?
Added By: c_adminCould you talk a little bit about your professional background and experience and give us some details about your clinical practice?
Added By: catalin_adminIn terms of volanesorsen, what were your thoughts on that product profile and the AdComm and the FDA action on that?
Added By: catalin_adminIn terms of the efficacy, would you say this is
hitting the mark?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
